Changing FDA Regulatory Environment Could Bolster Biotech, 'BBH'

Retrieved on: 2021-07-01 15:00:00

Tags for this article:

Life Sciences

Biogen

Spinal muscular atrophy

Industry economics)

Biotechnology companies

Exchange-traded funds

Moderna

Click the tags to see associated articles and topics

Changing FDA Regulatory Environment Could Bolster Biotech, 'BBH'. View article details on hiswai:

Excerpt

That could benefit biotechnology stocks and exchange traded funds, ... this year, is one of the more established biotechnology ETFs on the market, but ...

Article found on: www.etftrends.com

View Original Article